Suggested remit: To appraise the clinical and cost effectiveness of lurbinectedin with atezolizumab within its marketing authorisation for maintenance treatment of extensive-stage small-cell lung cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6526
Provisional Schedule
- Committee meeting:
- 05 August 2026
- Expected publication:
- 02 December 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Immedica Pharma (lurbinectedin)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- Lung Cancer Nursing UK
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Roche Products (atezolizumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 January 2026 | Invitation to participate |
| 22 May 2025 - 20 June 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6526 |
| 22 May 2025 | In progress. Scoping commenced |
| 16 April 2025 | Referral |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual